Vir Biotechnology (NASDAQ:VIR) Stock Price Breaks Below 200-Day Moving Average - Here's Why

Vir Biotechnology logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Vir Biotechnology shares fell below their 200-day moving average of $9.75, trading as low as $9.57 and last at $9.58.
  • Analyst sentiment remains broadly positive: the stock has a “Moderate Buy” consensus and an average price target of $22.57, despite ratings ranging from strong buy to sell.
  • Quarterly earnings were better than expected, with a loss of $0.57 per share versus the $0.75 forecast, but revenue missed estimates and fell 178.3% year over year.
  • MarketBeat previews top five stocks to own in December.

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) crossed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $9.75 and traded as low as $9.57. Vir Biotechnology shares last traded at $9.58, with a volume of 6,781,568 shares trading hands.

Wall Street Analyst Weigh In

A number of research analysts recently commented on VIR shares. Morgan Stanley boosted their price target on Vir Biotechnology from $25.00 to $28.00 and gave the company an "overweight" rating in a research note on Tuesday, November 10th. Needham & Company LLC raised their price objective on Vir Biotechnology from $18.00 to $20.00 and gave the company a "buy" rating in a report on Thursday, November 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vir Biotechnology in a report on Friday, October 2nd. Raymond James Financial restated a "strong-buy" rating on shares of Vir Biotechnology in a report on Monday, September 28th. Finally, Zacks Research upgraded Vir Biotechnology from a "strong sell" rating to a "hold" rating in a report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $22.57.

Check Out Our Latest Report on VIR

Vir Biotechnology Stock Performance

The stock has a market capitalization of $1.64 billion, a P/E ratio of -7.60 and a beta of 1.70. The business has a fifty day simple moving average of $11.11 and a 200-day simple moving average of $9.75.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.18. The company had revenue of ($0.19) million for the quarter, compared to analyst estimates of $0.98 million. During the same period last year, the business earned ($1.17) EPS. The business's quarterly revenue was down 178.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Vir Biotechnology, Inc. will post -1.28 earnings per share for the current year.

Insider Transactions at Vir Biotechnology

In other Vir Biotechnology news, EVP Vanina de Verneuil sold 2,407 shares of the firm's stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $11.10, for a total value of $26,717.70. Following the completion of the sale, the executive vice president directly owned 110,193 shares in the company, valued at approximately $1,223,142.30. This trade represents a 2.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Vir Biotechnology

Institutional investors have recently made changes to their positions in the stock. Voya Investment Management LLC grew its stake in shares of Vir Biotechnology by 2.3% in the 3rd quarter. Voya Investment Management LLC now owns 63,855 shares of the company's stock valued at $714,000 after buying an additional 1,457 shares during the period. Public Sector Pension Investment Board raised its stake in Vir Biotechnology by 3.5% during the 3rd quarter. Public Sector Pension Investment Board now owns 431,729 shares of the company's stock worth $4,650,000 after buying an additional 14,520 shares during the period. Edgestream Partners L.P. acquired a new position in Vir Biotechnology during the 3rd quarter worth approximately $3,800,000. ACT Capital Partners L.P. acquired a new position in Vir Biotechnology during the 3rd quarter worth approximately $559,000. Finally, Russell Investments Group Ltd. raised its stake in Vir Biotechnology by 65.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 136,146 shares of the company's stock worth $1,522,000 after buying an additional 53,987 shares during the period. Institutional investors and hedge funds own 65.32% of the company's stock.

About Vir Biotechnology

(Get Free Report)

Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases and cancer. Its research draws on immunology and includes approaches such as monoclonal antibodies, small-interfering RNA therapies and T-cell-based treatments. The company's pipeline has included programs targeting chronic hepatitis B and influenza, as well as investigational cancer therapies. Vir has also pursued research and development collaborations to advance its programs.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Vir Biotechnology Right Now?

Before you consider Vir Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vir Biotechnology wasn't on the list.

While Vir Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines